Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Array Biopharma

- PMLiVE

Second chance for AstraZeneca’s selumetinib with breakthrough designation

Part of R&D and commercial collaboration with MSD

Bristol Myers Squibb logo

BMS closes on Celgene merger after rebel investors bow out

News on Revlimid patent also positive

- PMLiVE

NICE green light for Imfinzi in groundbreaking early lung cancer treatment

Early treatment opens up possibility of cure

- PMLiVE

Pfizer hedges bets on gene therapy deal

Company not splashing out like Roche's Spark purchase

Bristol Myers Squibb logo

BMS defends Celgene buyout ahead of shareholder vote

BMS battles for hearts and minds before shareholder vote

- PMLiVE

Lynparza scores against pancreatic cancer

AZ and MSD drug success in BRCA-mutated disease

- PMLiVE

Merck & Co to buy IO specialists Immune Design for $300m

US giant looks to next generation technology

- PMLiVE

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial

Eli Lilly HQ

Lilly, Pfizer say NGF drug works in back pain too

Tanezumab was able to show a statistically significant improvement in pain

- PMLiVE

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

CNS penetration could give edge over rival

- PMLiVE

Advair generics and acquisitions to hit GSK in 2019

Earnings to decline as company transforms

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links